New drug combo for first-line treatment of extensive-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with extensive-stage small cell lung cancer.
- You must not have received any prior treatment for extensive-stage small cell lung cancer.
- You must be between 18 and 75 years old and have a good performance status (able to care for yourself and be up and about).
- You must have at least one measurable tumor that hasn't been previously treated with radiation, or if it has, it must have worsened after radiation and you must also have other measurable tumors.
- Your blood counts and organ function (kidney, liver, heart) must be within acceptable ranges.
- You must not have symptomatic brain metastases (unless they are stable for at least 1 month without steroids).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (BL-B01D1 plus immunotherapy) as a first treatment for people with advanced small cell lung cancer. It may be an option if you haven't had treatment yet and are healthy enough for chemotherapy.
This trial tests a new combination of drugs (BMS-986489 with chemotherapy) against the current standard treatment (atezolizumab with chemotherapy) for people who have just been diagnosed with extensive-stage small cell lung cancer. It aims to see which approach works better and is safer.
This trial tests a combination of two newer drugs (sacituzumab tirumotecan and anlotinib) for people with extensive-stage small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial is testing a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) as the first treatment for people with a rare type of cancer called LCNEC or EP-NEC that has spread. The goal is to see if this combination can help shrink or control the cancer and improve outcomes.
This study tests a new combination therapy for extensive-stage small cell lung cancer (cancer that has spread beyond the lung). The treatment includes an immunotherapy drug, a drug that blocks blood vessel growth to tumors, and chemotherapy. It aims to see how well this combination works in people who have not yet been treated for this cancer.
This study tests different drug combinations for extensive-stage small cell lung cancer, tailored to the cancer's biomarkers. It aims to find which treatment works best for patients newly diagnosed or whose cancer returns after initial treatment.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.